Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367874 | 0.85 | TSHR (0.48) | HSD17B10TSHRTDP1ALDH1A1EPHX2 | |
| SCHEMBL2368148 | 0.82 | MEN1 (0.47) | HSD17B10TSHRTDP1ALDH1A1EPHX2 | |
| SCHEMBL12890311 | 0.82 | TSHR (0.52) | HSD17B10TSHRALDH1A1EPHX2USP2 | |
| SCHEMBL11445081 | 0.82 | TSHR (0.52) | HSD17B10TSHRALDH1A1EPHX2USP2 | |
| SCHEMBL31602059 | 0.82 | MEN1 (0.47) | HSD17B10TSHRTDP1ALDH1A1EPHX2 | |
| SCHEMBL3122161 | 0.81 | ALDH1A1 (0.34) | HSD17B10TDP1ALDH1A1ALOX15 | |
| SCHEMBL20842923 | 0.80 | HSD17B10 (0.39) | HSD17B10TSHRTDP1EPHX2 | |
| SCHEMBL8013962 | 0.80 | — | — | |
| SCHEMBL497428 | 0.80 | — | — | |
| SCHEMBL8008044 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135520-A1 | Cis-trans isomerisation of semicarbazone compounds | BASF AKTIENGESELLSCHAFT (DE) | 2007-06-14 | — | — | US | disclosed |
| US-7135491-B2 | 5-Aryltetrazole compounds and uses thereof | INOTEK PHARMACEUTICALS CORP. (US) | 2006-11-14 | — | — | US | disclosed |
| US-7087631-B2 | Aryltetrazole compounds, and compositions thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060135519-A2 | 5-ARYLTETRAZOLE COMPOUNDS AND COMPOSITIONS THEREOF | NIVOROZHKIN ALEXANDER | 2006-06-22 | — | — | US | disclosed |
| US-20050159418-A1 | 5-Aryltetrazoles compounds and compositions thereof | NIVOROZHKIN ALEX (US) | 2005-07-21 | — | — | US | disclosed |
| US-20050159467-A1 | 5-Aryltetrazole compounds and uses thereof | NIVOROZHKIN ALEX (US) | 2005-07-21 | — | — | US | disclosed |
| EP-1542980-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | Inotek Pharmaceuticals Corporation (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040116423-A1 | 5-Aryltetrazole compounds, compositions thereof, and uses therefor | INOTEK PHARMACEUTICALS CORPORATION | 2004-06-17 | — | — | US | disclosed |
| WO-2004009563-A1 | 5-ARYLTETRAZOLE COMPOUNDS, COMPOSITIONS THEREOF, AND USES THEREFOR | INOTEK PHARMACEUTICALS CORPORATION (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135519-A2 | 5-ARYLTETRAZOLE COMPOUNDS AND COMPOSITIONS THEREOF | CASP5, NOX5, IL5 | HSD17B10 885/4885TSHR 2774/4885TDP1 1456/4885 |
| US-20070135520-A1 | Cis-trans isomerisation of semicarbazone compounds | SLC16A1, SLC16A3, PIN1 | HSD17B10 1238/4885TSHR 2257/4885TDP1 4374/4885 |
| US-20050159467-A1 | 5-Aryltetrazole compounds and uses thereof | NLRP3, XDH, CASP5 | HSD17B10 703/4885TSHR 2226/4885TDP1 1263/4885 |
| US-20050159418-A1 | 5-Aryltetrazoles compounds and compositions thereof | NLRP3, CASP5, CASP3 | HSD17B10 603/4885TSHR 2648/4885TDP1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.